Early and delayed IL-1 beta modulating antibody, gevokizumab, treatments limit cardiac remodeling and reverse coronary endothelial dysfunction following myocardial infarction injury in diabetic rats
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.